肝癌免疫治疗的假性进展探索

(C10第十届中国肿瘤介人与微创治疗大会(CC102019)】The 10th China Conference on Interventional Oncology CClO 2019ON6的n0aoow城CN COLG暨2019年中国抗意协会肿瘤介人学分会年会免疫检查点抑制剂加速获批多种适应症Nivolumab makes headwinds into HCC 2015Ipilimumab●Melanoma(une2000)Nivolumab●Melanoma●HNC●NSCLC●Jrothelial●RCC●MSh●HDOHCCIpilimumab+Nivolumab●MelanomaPembrolizumab●Melanoma●UrothelialNSCLC●●HNC●HD●MS-hOGEJ●First patient dosedAtezolizumab●Urothelial●First FDA approvals●NSCLCfor indicationDurvalumab●BladderAvelumab●MerkelUrothelial●20002006200820102012201420162018Fig.2.Timing of clinical development of anti-CTLA-4,anti-PD-1,and anti-PD-L1 antibodies,from first administration to humans to FDA approval.Ribas et al.,Science 359,1350-1355 (2018)